2025年上半年全球药品销售额TOP50出炉

Group 1: Pharmaceutical Sales Overview - The Insight database released the TOP 50 pharmaceutical sales list for the first half of 2025, highlighting that chemical drugs and monoclonal antibodies dominate the list, with additional contributions from dual antibodies, preventive vaccines, ADCs, and fusion proteins [1] - A total of 44 drugs exceeded $2 billion in sales, with 10 surpassing $5 billion, and 3 drugs exceeding $10 billion in sales [1] - Semaglutide, with sales of $16.632 billion from its three versions (Ozempic, Rybelsus, and Wegovy), surpassed Keytruda, which maintained $15.161 billion in sales, to take the top position [1] Group 2: CDK4/6 Inhibitors Market Dynamics - The CDK4/6 inhibitor market is characterized by intense competition among major pharmaceutical companies, with Pfizer's Ibrance initially leading the market [2] - However, the market dynamics shifted as Eli Lilly's Verzenio gained significant traction, and in 2024, it surpassed Ibrance in sales for the first time [2] - In the first half of this year, Ribociclib experienced a remarkable growth rate of 58.7%, generating $2.133 billion, while Abemaciclib led the market with $2.648 billion, and Ibrance fell to $2.026 billion [2] Group 3: BTK Inhibitors Market Analysis - There are currently six approved BTK inhibitors globally, with Ibrutinib, Acalabrutinib, and Zanubrutinib holding over 97% of the market share [3] - Ibrutinib, despite its initial success with sales reaching $9.777 billion in 2021, has seen a decline, with sales dropping below $3 billion in the first half of 2025, a 9% year-over-year decrease [3] - In contrast, Zanubrutinib has shown impressive growth, achieving $2.644 billion in sales for 2024, a 103.4% increase, and breaking into the TOP 50 list with $1.742 billion in the first half of 2025, a 54.7% year-over-year growth [3]